CMMB Chemomab Therapeutics
- 2.140
- +0.190+9.74%
- 2.140
- 0.0000.00%
Chemomab Therapeutics News
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4
Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Cuts Target Price to $11
Chemomab Therapeutics Analyst Ratings
Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $9
Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $9
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4
Chemomab Therapeutics (CMMB) Gets a Buy From Oppenheimer
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4
Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $9
Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $13
Chemomab Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Chemomab Therapeutics (CMMB), Fate Therapeutics (FATE) and Disc Medicine (IRON)
Analysts Offer Insights on Healthcare Companies: Andlauer Healthcare Group (OtherANDHF), ACADIA Pharmaceuticals (ACAD) and Chemomab Therapeutics (CMMB)
Chemomab Therapeutics Analyst Ratings
Chemomab Therapeutics Analyst Ratings
Roth MKM Reinstates Buy on Chemomab Therapeutics, Maintains $7 Price Target
Chemomab Therapeutics Analyst Ratings
Oppenheimer Reaffirms Their Hold Rating on Chemomab Therapeutics (CMMB)
Roth MKM Initiates Coverage On Chemomab Therapeutics With Buy Rating, Announces Price Target of $7
Chemomab Therapeutics Analyst Ratings
No Data